December 21, 2016 10:12 AM EST
R&D

Gala­pa­gos, Ab­b­Vie glimpse ear­ly progress in search of a cys­tic fi­bro­sis triple to ri­val Ver­tex

Arsalan Arif

Founder

Ab­b­Vie $AB­BV and its part­ner Gala­pa­gos $GLPG are pleased with some of the ear­ly da­ta they’re see­ing for one piece of their triple drug puz­zle …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times